RAMM Pharma Corp. Provides Update on Canada post strike and mailing of the Company´s meeting materials
pharmaceutical-investing RAMM Pharma Announces Approval and Registration of Epifractán™ 2 Percent by Peru’s Ministry of Health
pharmaceutical-investing RAMM Pharma Announces Approval and Registration of Epifractán™ 5 Percent by Peru’s Ministry of Health and Enters Distribution Agreement to Supply Pharmacies in Peru
RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution
pharmaceutical-investing RAMM Pharma Corp. Provides Details on Operational Activities to Support COVID-19 Medical Response Effort & Corporate Update
RAMM Pharma Corp. to Acquire NettaLife, a Leading Developer of Cannabis-Based Products for Pets and Large Animals
RAMM Pharma Corp. (formerly MTC Growth Fund-I Inc.) Announces Closing of Business Combination with RAMM Pharma Holdings Corp., Medic Plast S.A. and Yurelan S.A.; Trading Anticipated to Commence November 8, 2019
RAMM Pharma and MTC Announce Receipt of Conditional Approval to List on the CSE and Provide an Update on Transaction Status
